The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | The impact of durvalumab for resectable non-small cell lung cancer
Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the importance of tailoring therapies to individual patient presentations. The recent approval of durvalumab for resectable non-small cell lung cancer (NSCLC) highlights the role of immunotherapy and targeted therapies, and its efficacy in both operable and inoperable tumors. Neoadjuvant and consolidation therapies are discussed for surgical candidates, while radiation and alternative treatments are considered for non-surgical patients. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
